Ormeloxifene


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Dysfunctional uterine bleeding 60 mg twice a wk for the 1st 12 wk, then 60 mg/wk for up to next 12 wk. Contraception 30 mg twice a wk for the 1st 12 wk, then 30 mg/wk from 13th wk onwards. Take 1st tab on the 1st day of menstrual cycle. Follow dose irrespective of menstrual periods.
Dosage Details
Oral
Contraception
Adult: Take 1 tablet (30 mg) twice a wk for the 1st 12 wk then 1 tablet (30 mg) once a wk from 13th wk onwards. Take 1st tablet on the 1st day of menstrual cycle. Follow dose irrespective of menstrual periods.

Oral
Dysfunctional uterine bleeding
Adult: 60 mg twice a wk for the 1st 12 wk and then 60 mg once a wk for up to next 12 wk.
Contraindications
Polycystic ovarian disease, cervical hyperplasia, recent history of jaundice or hepatic impairment, severe allergic states, TB, renal impairment. Pregnancy and lactation.
Special Precautions
Women who desire to be pregnant should discontinue taking the drug.
Adverse Reactions
Delayed menses.
Action
Description: Ormeloxifene acts on oestrogen receptors. It has a weak estrogenic and potent antiestrogenic actions. It is expected to exert a contraceptive effect and normalise the bleeding from uterine cavity by regularising the expression of oestrogen receptors on the endometrium. As a contraceptive, it prevents proliferation and decidualisation of the endometrium, enhances blastocyst formation and slightly increases embryo transport through the oviducts.
Pharmacokinetics:
Absorption: Well absorbed from the GI tract. Peak serum levels achieved in 4 hr.
Distribution: Widely distributed in tissues. Little affinity to plasma proteins.
Excretion: Terminal half-life: Approx 170 hr.
Disclaimer: This information is independently developed by MIMS based on Ormeloxifene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in